

CONTENTS

List of Tables	i- v
List of Figures	vi-x
Chapter 1: Introduction	
1.1.	Introduction 1
1.2.	Proposed plan of work 3
1.2.1.	Microemulsion 4
1.2.2.	Solid Lipid Nanoparticles (SLN) 4
Chapter 2: Literature review:	
2.1.	Introduction 6
2.2.	Classification of lipid-based systems: 8
2.3.	Overview of colloidal drug carrier systems 9
2.3.1.	Nanosuspensions 9
2.3.2.	Liposomes 10
2.3.3.	Mixed micelles 11
2.3.4.	Colloidal liquid crystalline structures 13
2.3.5.	Nanocapsules 14
2.3.6.	Nanoemulsion 15
2.3.7.	Microemulsions 16
2.3.7.1.	Structure of microemulsion: 17
2.3.7.2.	Solubility studies 20
2.3.7.3.	Difference from emulsion 20
2.3.7.4.	Theories for microemulsion formation 20
2.3.7.5.	Advantages of microemulsion 21
2.3.7.6.	Formulation consideration 22

	2.3.7.6.1.	Surfactant	22
	2.3.7.6.2.	Co-surfactant	27
	2.3.7.6.3.	Oils	29
	2.3.7.6.4.	Temperature	29
	2.3.7.6.5.	Surfactant-Cosurfactant ratio	30
	2.3.7.7.	Phase diagram	30
	2.3.7.8.	Microemulsion characterization	31
	2.3.7.9.	Storage Stability	34
	2.3.7.10.	Application of Microemulsion as Drug Delivery System	34
	2.3.7.10.1.	Influence on Drug Release Characteristics	34
	2.3.7.10.2.	For Topical Delivery	35
	2.3.7.10.3.	Oral delivery	37
	2.3.7.10.4.	Parenteral, Pulmonary and Ocular Delivery	39
2.3.8.		Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC)	40
	2.3.8.1.	Preparation of SLNs:	41
	2.3.8.2	Drug uptake by solid lipid nanoparticles	43
	2.3.8.3.	Release of drug from SLNs:	44
	2.3.8.4.	Crystallinity of the Lipid phase:	45
2.3.9.		Polymer nanoparticles	49
References			51
2.4.		Profile of Acyclovir	75
2.4.1.		Introduction	75

2.4.2.	Description	75
2.4.3.	Chemical name	75
2.4.4.	Structural Formula	75
2.4.5.	Molecular Formula	75
2.4.6	Molecular weight	75
2.4.7.	Physicochemical properties	75
2.4.7.1.	Solubility	75
2.4.7.2.	pKa	75
2.4.8.	Clinical pharmacology	76
2.4.8.1.	Mechanism of action	76
2.4.8.2.	Antiviral activities	76
2.4.9.	Uses	77
2.4.10.	Pharmacokinetic	78
2.4.10.1.	Absorption	78
2.4.10.2.	Distribution:	79
2.4.10.3.	Elimination	79
2.4.11.	Indication	80
2.4.12.	Dosage and administration	80
2.4.13.	Contraindication	80
2.4.14.	Storage	81
2.4.15.	Adverse effects	81
2.4.15.1.	Herpes Simplex	81
2.4.15.2.	Herpes Zoster	81
2.4.15.3.	Chickenpox	82

2.4.15.4.	Observation during clinical practice	82
2.4.16.	Overdosage	83
2.4.17	Precaution	83
2.4.18.	Quantitative method	84
2.4.18.1.	HPLC	84
2.4.18.2.	Radioactivity measurements	85
2.4.18.3.	LC-MS-MS system	86
2.4.18.4.	High-performance capillary electrophoresis	86
References		88
2.5.	Profile of efavirenz	91
2.5.1.	Introduction	91
2.5.2.	Description	91
2.5.2.1	Chemical name	91
2.5.2.2.	Structural Formula	91
2.5.2.3.	Molecular Formula	91
2.5.2.4.	Molecular weight	91
2.5.2.5.	Solubility	91
2.5.3.	Clinical pharmacology	91
2.5.4.	Uses	92
2.5.5.	Pharmacokinetic	92
2.5.5.1.	Absorption	92
2.5.5.2.	Effect of Food on Oral Absorption	92
2.5.5.3.	Distribution	93
2.5.5.4.	Metabolism	93

2.5.5.5.	Elimination	93
2.5.6.	Indication	94
2.5.7.	Dosage and administration	94
2.5.8.	Contraindication	94
2.5.9.	Storage	94
2.5.10.	Adverse effects	94
2.5.11.	Overdose	95
2.5.12.	Precaution	95
2.5.13. 2.5.13.1.	Quantitative method	95
2.5.13.2	HPLC	95
2.5.13.3.	LC/MS/MS method	97
2.5.13.4.	Radioactivity Assay.	98
References		99
Chapter 3: Analytical methods:		
3.1	Introduction	101
3.2	Experimental	101
3.2.1.	Drugs	101
3.2.2.	Reagents	101
3.2.3.	Apparatus	102
3.4.	Acyclovir	102
3.4.1.	Estimation of acyclovir in 0.1N HCl	102
3.4.1.1.	Solution	102
3.4.1.2.	Procedure for calibration curve	102
3.4.1.3.	Stability of the solution	103

3.4.2.	Estimation of acyclovir in ethanol	104
3.4.2.1.	Solution	104
3.4.2.2.	Procedure for calibration curve	104
3.4.2.3	Stability and selectivity	105
3.4.2.4.	Estimation of acyclovir from drug-oil mixture, microemulsion and SLN or its supernatant	105
3.4.3.	Estimation of acyclovir in phosphate buffer saline (PBS) pH 7.4	107
3.4.3.1.	Solution	107
3.4.3.2.	Procedure for calibration curve	107
3.4.3.3	Stability of the solution	109
3.4.4.	Estimation of acyclovir in rat plasma	109
3.4.4.1.	Chromatographic system	110
3.4.4.2.	Chromatographic conditions	110
3.4.4.3.	Calibration curve in rat plasma	110
3.4.4.4.	Validation of the HPLC method	110
3.5.	Efavirenz	111
3.5.1	Estimation of Efavirenz in methanol	111
3.5.1.1.	Solution	111
3.5.1.2.	Procedure for calibration curve	111
3.5.1.3.	Stability and selectivity	112
3.5.2.	Estimation of efavirenz from drug-oil mixture, microemulsion and SLN or its supernatant	112

3.5.2.1.	Estimation of efavirenz from SLN / supernatant	112
3.5.3.	Estimation of Efavirenz in 1% SLS	114
3.5.3.1.	Solution	114
3.5.3.2.	Procedure for calibration curve	114
3.5.4.	Estimation of efavirenz in rat plasma	117
3.5.4.1.	Chromatographic system	117
3.5.4.2.	Chromatographic conditions	117
3.5.4.3.	Calibration curve in standard solution	117
3.5.4.4.	Calibration curve in rat plasma	119
3.6.	Results and discussion	121
3.6.1.	Estimation of acyclovir in 0.1N HCl	121
3.6.2.	Estimation of acyclovir in ethanol	121
3.6.3.	Estimation of acyclovir in phosphate buffer saline (PBS) pH 7.4	122
3.6.4.	Estimation of acyclovir in rat plasma	123
3.6.4.1.	Calibration curve in rat plasma	125
3.6.4.2.	Validation of the HPLC method	127
3.6.5.	Estimation of efavirenz in methanol	128
3.6.6.	Estimation of efavirenz in 1% SLS	129
3.6.7.	Estimation of efavirenz in rat plasma	129
References		132

Chapter 4: Preparation of microemulsions

4.1	Introduction	133
4.2.	Experimental	133
4.2.1.	Drugs	133
4.2.2.	Reagents	133
4.2.3.	Equipments	134
4.3.	Solubility of acyclovir and efavirenz in different oil phase and in surfactant	134
4.4.	Interfacial tension measurements	134
4.5.	Preparation of microemulsion	135
4.6.	Construction of phase diagram:	135
4.6.1.	Acyclovir	136
4.6.1.1.	Phase diagram for labrasol, plurol olique, labrafac and water system (System A)	136
4.6.1.2.	Phase diagram for Tween 80, propylene glycol, labrafac and water system (System B)	138
4.6.2.	Efavirenz	139
4.6.2.1.	Labrasol, transcuto1, labrafil M 1944 CS and water system (System C)	139
4.6.2.2	Cremophor RH 40, propylene glycol, labrafil M 1944C and water system (System D)	140
4.7.	Incorporation of drug into the microemulsion system	142
4.7.1.	Acyclovir	142
4.7.2.	Efavirenz	142

4.8	Results and Discussion	143
4.8.1.	Interfacial tension measurements	144
4.8.1.1.	Acyclovir	144
4.8.1.1.1.	Labrasol, plurol olique, labrafac and water system (System A)	144
4.8.1.1.2.	Tween 80, propylene glycol, labrafac and water system (System B)	146
4.8.2	Efavirenz	148
4.8.2.1	Labrasol transcutool, labrafil M 1944 CS and water system (System C)	148
4.8.2.2.	Cremophor RH 40, propylene glycol, labrafil M 1944C and water system (System D)	150
4.9.	Preparation of microemulsion	152
4.9.1.	Acyclovir	152
4.9.1.1.	Labrasol, plurol olique, labrafac and water system (System A):	152
4.9.1.2.	Tween 80, propylene glycol, labrafac and water system (System B)	154
4.9.2.	Efavirenz	155
4.9.2.1	Labrasol transcutool, labrafil M 1944 CS and water system (System C):	155
4.9.2.2.	Cremophor RH 40, propylene glycol, labrafil M 1944CS and water system (System D)	157
4.10	Phase diagram:	158
4.10.1	Acyclovir	158
4.10.1.1	Labrasol, plurol olique, labrafac and water	159

	system (System A)	
4.10.1.2.	Tween 80, propylene glycol, labrafac and water system (System B)	161
4.10.2.	Efavirenz	164
4.10.2.1.	Labrasol, transcuto1, labrafil M 1944 CS and water system (System C):	164
4.10.2.2.	Cremophor RH 40, propylene glycol, labrafil M 1944 CS and water system (System D)	166
4.11.	Incorporation of drug into the microemulsion system:	169
4.11.1.	Acyclovir	169
4.11.2.	Efavirenz	170
4.12.	Conclusion	171
4.12.1.	Acyclovir	171
4.12.2.	Efavirenz	171
Reference:		172
Chapter 5: Characterization of microemulsions		
5.1	Introduction	173
5.2	Experimental	173
5.2.1	Apparatus	173
5.2.2.	Selection of microemulsion formulations	173
5.2.2.1.	Acyclovir	173
5.2.2.1.1	Detailed studies on Labrasol, plurol olique, labrafac and water (System A)	174
5.2.2.1.2.	Detailed studies on Tween 80, propylene	175

	glycol, labrafac and water system (System B)	
5.2.2.2.	Efavirenz	176
5.2.2.2.1.	Detailed studies on Labrasol transcuto1, labrafil M 1944 CS and water system (System C)	176
5.2.2.2.2.	Detailed studies on cremophor RH 40, propylene glycol, labrafil M 1944CS and water system (System D)	177
5.2.3.	Drug content of microemulsion	179
5.2.3.1.	Acyclovir	179
5.2.3.2.	Efavirenz	179
5.2.4.	Electro conductive measurement and percolation threshold	179
5.2.5.	Viscosity measurements	180
5.2.6.	Dilution effect and particle size measurements	180
5.2.7.	Zeta potential measurements	180
5.2.8.	Refractive index and % Transmittance	181
5.2.9.	pH Determination	181
5.2.10.	In vitro intestinal permeability studies	181
5.2.10.1.	Acyclovir	181
5.2.10.2.	Efavirenz	182
5.2.11.	Data analysis	182
5.2.11.1.	Percent Drug Diffusion	182
5.2.11.2.	Kinetics of release	183

5.2.12.	Permeation data analysis	183
5.2.13.	Transmission Electron Microscopy (TEM)	183
5.2.14	Stability studies	184
5.2.13.1.	Visual Inspection	184
5.2.13.2.	Centrifugation	184
5.2.13.3.	Freeze–thaw cycles	184
5.2.13.4.	Temperature effect on particle size of microemulsions	184
5.3.	Results and discussion	185
5.3.1.	Drug content in microemulsion	185
5.3.1.1.	Acyclovir	185
5.3.1.2.	Efavirenz	185
5.3.2.	Electro conductive measurement and percolation threshold	186
5.3.2.1.	Acyclovir	186
5.3.2.1.1.	Studies on Labrasol, plurol olique, labrafac and water system (System A):	186
5.3.2.1.2.	Studies on tween 80, propylene glycol, labrafac and water system (System B)	188
5.3.2.2.	Efavirenz	192
5.3.2.2.1.	Studies on labrasol, transcutol, labrafil M 1944 CS and water system (System C)	192
5.3.2.2.2.	Studies on cremophor RH 40, propylene glycol, labrafil M 1944CS and water system (System D)	195

5.3.3.	Viscosity measurements	196
5.3.3.1.	Acyclovir	196
5.3.3.1.1.	Labrasol, plurol olique, labrafac and water system (System A)	197
5.3.3.1.2.	Studies on tween 80, propylene glycol, labrafac and water system (System B)	199
5.3.3.2.	Efavirenz	200
5.3.3.2.1.	Studies on labrasol, transcutool, labrafil M 1944 CS and water system (System C)	201
5.3.3.2.2.	Studies on cremophor RH 40, propylene glycol, labrafil M 1944CS and water system (system D)	201
5.3.4.	Dilution effect and particle size measurements	203
5.3.4.1.	Acyclovir	204
5.3.4.1.1.	Studies on labrasol, plurol olique, labrafac and water system (System A)	205
5.3.4.1.2.	Studies on tween 80, propylene glycol, labrafac and water system (System B)	206
5.3.4.2.	Efavirenz	208
5.3.4.2.1.	Studies on labrasol, transcutool, labrafil M1944CS and water system (System C)	209
5.3.4.2.2.	Studies on Cremophor RH 40, propylène glycol, labrafil M 1944CS and water system (system D)	210
5.3.5.	Zeta potential measurements	211

5.3.6.	Refractive index and % Transmittance	212
5.3.7.	pH Determination	213
5.3.8.	In vitro intestinal permeability studies	213
5.3.8.1.	Acyclovir	213
5.3.8.1.1.	Labrasol, plurol olique, labrafac and water system (System A)	213
5.3.8.1.2.	Tween 80, propylene glycol, labrafac and water system (System B)	215
5.3.8.2.	Efavirenz:	217
5.3.8.2.1.	Labrasol, transcuto1, labrafil M 1944CS and water system (System C)	217
5.3.8.2.2.	Cremophor RH 40, propylene glycol, labrafil M 1944CS and water system (System D)	218
5.3.9.	Transmission electron microscopy (TEM)	220
5.3.10.	Stability studies	222
Reference:		223
Chapter 6: Preparation and characterization of SLN:		
6.1	Introduction	225
6.2.	Instruments	226
6.3	Materials	226
6.4.	Method of SLN preparation	226
6.4.1.	Acyclovir	228
6.4.2.	Efavirenz	228
6.5.	Characterizations of SLN	229
6.5.1.	Particle size measurements	229

6.5.2.	Estimation of drug entrapment efficiency (DEE)	229
6.5.2.1.	Acyclovir	230
6.5.2.2.	Efavirenz	230
6.5.3.	Lyophilization of nanoparticles dispersions	230
6.5.4.	Optimization of homogenization pressure	231
6.5.5.	Optimization of number of homogenization cycles	231
6.5.6.	Optimization of drug loading	231
6.5.7.	Differential Scanning Calorimeter study (DSC)	231
6.5.8.	Scanning electron microscopy (SEM)	231
6.5.9.	Zeta Potential Measurement	232
6.5.10.	Preparation of membrane for release study	232
6.5.11.	In vitro diffusion studies	233
6.5.12.	Data analysis	233
6.5.12.1.	Percent Drug Diffusion	233
6.5.12.2.	Kinetics of release	233
6.5.13.	Permeation data analysis	234
6.5.14.	The physical stability of SLN in dispersions	234
6.6.	Results and Discussion	235
6.6.1.	Preparation of SLN	235
6.6.1.1.	Acyclovir	235
6.6.1.2.	Efavirenz	238

6.6.2.	Particle size analysis and Drug Entrapment Efficiency (DEE)	241
6.6.3.	Optimization of homogenization pressure	243
6.6.4.	Optimization of number of homogenization cycles	243
6.6.5.	Optimization of drug loading	244
6.6.5.1.	Acyclovir	244
6.6.5.2.	Efavirenz	245
6.6.6.	Differential Scanning Calorimetry (DSC)	246
6.6.7.	Scanning electron microscopy (SEM)	250
6.6.8.	Zeta Potential Measurement	251
6.6.9.	In-vitro diffusion:	252
6.6.9.1.	Acyclovir	254
6.6.9.2.	Efavirenz	254
6.6.10.	Stability study	257
Reference:		260
Chapter 7: In vivo studies:		
7.1	Introduction	263
7.2	Calculation of dose	263
7.3.	In-vivo absorption study	264
7.4.	HPLC analysis of plasma sample	265
7.4.1	Acyclovir	265
7.4.2.	Efavirenz	265
7.5.	Pharmacokinetic data analysis	266

7.6.	Statistical analysis	267
7.7.	Results	268
7.7.1	Acyclovir	268
7.7.2	Efavirenz	270
7.8.	Discussion	273
References:		277
Chapter 8: Toxicity studies		
8.1.	Introduction	279
8.1.1.	Acyclovir	279
8.1.2.	Efavirenz	279
8.2.	Experimental procedure	279
8.2.1.	Animals	279
8.2.2.	Nephro-toxicity study of acyclovir and its microemulsion & SLN formulations	279
8.2.3.	Hepato-toxicity study of efavirenz and its microemulsion & SLN formulations	280
8.3.	Results and discussion	280
8.3.1.	Nephro-toxicity studies	280
8.3.2.	Hepato-toxicity studies	283
References		287
Chapter 9: Summary and conclusion:		
9.1	Introduction	288
9.1.1.	Acyclovir	290
9.1.2.	Efavirenz	290
9.2.	Preparation of microemulsion:	291

9.2.1.	Acyclovir	291
9.2.2.	Efavirenz	292
9.3.	Characterizations of microemulsion	292
9.3.1.	Acyclovir	292
9.3.2.	Efavirenz	293
9.4.	Preparation and characterization of SLN	293
9.4.1.	Acyclovir	295
9.4.2.	Efavirenz	296
9.5.	<i>In-Vivo</i> bioavailability evaluation	297
9.5.1.	Acyclovir	297
9.5.2.	Efavirenz	297
9.6.	Toxicity study of the formulations	298
9.6.1.	Acyclovir	298
9.6.2.	Efavirenz	298
9.7.	Conclusion	299